Therapeutic peptides for cancer therapy. Part II - Cell cycle inhibitory peptides and apoptosis-inducing peptides

Expert Opinion on Drug Delivery

Volumn 6, Issue 10, 2009, Pages 1049-1064

  Raucher, Drazen ^a   Moktan, Shama ^a   Massodi, Iqbal ^a   Bidwell III, Gene L ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Bcl 2; Drug delivery; p16; p21; p27; Smac; Therapeutic peptide

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BAD BH3 FUSION PROTEIN; BAD BH3 PENETRATIN FUSION PROTEIN; BAK BH3 FUSION PROTEIN; BH3 PROTEIN; BID BH3 FUSION PROTEIN; BIM PROTEIN; C4 TAT FUSION PROTEIN; CASPASE 3; CASPASE 9; CPM 1285; CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; HYBRID PROTEIN; PEN ELP P21 FUSION PROTEIN; PENETRATIN P16 FUSION PROTEIN; PEPTIDE DERIVATIVE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; R9 P16 FUSION PROTEIN; TAT BIM FUSION PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PROSTATE TUMOR; PROTEIN PROTEIN INTERACTION; REVIEW; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; APOPTOSIS; CELL CYCLE; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES;

EID: 70349383205     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903158909     Document Type: Review

References (106)

1. Lipka E, Crison J, Amidon GL. Transmembrane transport of peptide type compounds: prospects for oral delivery. J Control Release 1996;39(2-3):121-129 (Pubitemid 26194211)
2. Talmadge JE. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998;33(3):241-252
3. Derossi D, Joliot AH, Chassaing G, et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994;269(14):10444-10450 (Pubitemid 24198241)
4. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272(25):16010-16017 (Pubitemid 27265584)
5. Lin YZ, Yao SY, Veach RA, etal. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270(24):14255-14258
6. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998;8(2):84-87 (Pubitemid 28056816)
7. Lundberg P, Langel U. A brief introduction to cell-penetrating peptides. J Mol Recognit 2003;16(5):227-233
8. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005;57(4):637-651 (Pubitemid 40255564)
9. Leuschner C, Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 2004;10(19):2299-2310 (Pubitemid 38855038)
10. Fischer PM, Lane DP. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr Med Chem 2000;7(12):1213-1245 (Pubitemid 30822349)
11. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375(6527):159-161 •• This paper first identified domains of p21 capable of inhibiting cell proliferation, and determined which regions interacted with the cyclin/Cdk and which interacted with PCNA.
12. Chen IT, Akamatsu M, Smith ML, et al. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene 1996;12(3):595-607 (Pubitemid 126423786)
13. Bonfanti M, Taverna S, Salmona M, et al. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997;57(8):1442-1446 (Pubitemid 27175558)
14. Warbrick E, Lane DP, Glover DM, etal. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol 1995;5(3):275-282
15. Pan ZQ, Reardon JT, Li L, etal. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem 1995;270(37):22008- 22016
16. Ball KL, Lain S, Fahraeus R, et al. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 1997;7(1):71-80 (Pubitemid 27058942)
17. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998;16(3):311-320 (Pubitemid 28052285)
18. Mutoh M, Lung FD, Long YQ, et al. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 1999;59(14):3480-3488 (Pubitemid 29334512)
19. Mattock H, Lane DP, Warbrick E. Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp Cell Res 2001;265(2):234-241 • This paper demonstrates the utility of attaching a peptide to a larger protein carrier to increase its stability. (Pubitemid 32980211)
20. Urry DW, Luan C-H, Parker TM, et al. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J Am Chem Soc 1991;113:4346-4348
21. Liu W, Dreher MR, Chow DC, et al. Tracking the invivo fate of recombinant polypeptides by isotopic labeling. J Control Release 2006;114(2):184-192 (Pubitemid 44291852)
22. Meyer DE, Kong GA, Dewhirst MW, et al. Targeting a genetically engineered elastin like polypeptide to solid tumors by local hyperthermia. Cancer Res 2001;61(4):1548-1554
23. Liu W, Dreher MR, Furgeson DY, et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice.J Control Release 2006;116(2):170-178
24. Dreher MR, Liu W, Michelich CR, et al. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res 2007;67(9):4418-4424 (Pubitemid 46815091)
25. Massodi I, Bidwell GL 3rd, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005;108(2-3):396-408 • This paper describes a thermally responsive carrier for TPs. (Pubitemid 41608671)
26. Sadler K, Eom KD, Yang JL, et al. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002;41(48):14150- 14157 (Pubitemid 35403333)
27. Massodi I, Moktan S, Rawat A, et al. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive elastin like polypeptide carrier. Int J Cancer 2009. In press • This paper describes a thermally responsive carrier for a p21 peptide.
28. Fåhraeus R, Paramio JM, Ball KL, et al. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 1996;6(1):84-91 • This paper describes a p16 mimetic peptide.
29. Fahraeus R, Lain S, Ball KL, et al. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene 1998;16(5):587-596 (Pubitemid 28062338)
30. Fujimoto K, Hosotani R, Miyamoto Y, et al. Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells. Cancer Lett 2000;159(2):151-158
31. Hosotani R, Miyamoto Y, Fujimoto K, et al. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res 2002;8(4):1271-6 •• This paper describes the application of the p16 peptide in vivo in a mouse model of pancreatic cancer. (Pubitemid 35177384)
32. Kondo E, Seto M, Yoshikawa K, et al. Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol Cancer Ther 2004;3(12):1623-1630 (Pubitemid 40136718)
33. Midgley CA, Desterro JM, Saville MK, et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination invitro and can activate p53 invivo. Oncogene 2000;19(19):2312-2323
34. Kondo E, Tanaka T, Miyake T, et al. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines. Mol Cancer Ther 2008;7(6):1461-1471
35. Fåhraeus R, Lane DP. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 1999;18(8):2106-18 • This paper describes a promising alternative use for the p16 peptide as an anti-metastatic agent.
36. Slomiany P, Baker T, Elliott ER, et al. Changes in motility, gene expression and actin dynamics: Cdk6-induced cytoskeletal changes associated with differentiation in mouse astrocytes. J Cell Biochem 2006;99(2):635-646 (Pubitemid 44435579)
37. Alhaja E, Adan J, Pagan R, et al. Anti-migratory and anti-angiogenic effect of p16: a novel localization at membrane ruffles and lamellipodia in endothelial cells. Angiogenesis 2004;7(4):323-333 (Pubitemid 40767934)
38. Andrews MJ, McInnes C, Kontopidis G, et al. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem 2004;2(19):2735-2741
39. Gondeau C, Gerbal-Chaloin S, Bello P, et al. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J Biol Chem 2005;280(14):13793-13800 (Pubitemid 40517276)
40. Adams PD, Sellers WR, Sharma SK, et al. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 1996;16(12):6623-6633
41. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96(8):4325-4329
42. Adams PD, Li X, Sellers WR, et al. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol Cell Biol 1999;19(2):1068-1080 (Pubitemid 29046850)
43. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84(14):5034-5037
44. Bellacosa A, Testa JR, Staal SP, et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254(5029):274-277 (Pubitemid 21917339)
45. Franke TF, Kaplan DR, Cantley LC, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997;275(5300):665-668
46. del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278(5338):687-689 (Pubitemid 27464966)
47. Datta SR, Dudek H, Tao X, etal. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91(2):231-241
48. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282(5392):1318-1321 (Pubitemid 28524494)
49. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999;18(49):6910-6924
50. Lutz RJ. Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins. Biochem Soc Trans 2000;28(2):51-56
51. Laine J, Kunstle G, Obata T, etal. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000;6(2):395-407
52. Hiromura M, Okada F, Obata T, et al. Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. J Biol Chem 2004;279(51):53407-53418 • This paper demonstrates that a peptide from TCL1 can inhibit Akt activity. (Pubitemid 40051845)
53. Luo Y, Smith RA, Guan R, et al. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 2004;43(5):1254-1263 (Pubitemid 38176523)
54. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995;92(17):7834-7838
55. Diaz JL, Oltersdorf T, Horne W, etal. A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. J Biol Chem 1997;272(17):11350-11355 (Pubitemid 27184138)
56. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997;275(5302):983-986 (Pubitemid 27087715)
57. Cosulich SC, Worrall V, Hedge PJ, et al. Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol 1997;7(12):913-920 (Pubitemid 28017068)
58. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999;274(19):13298-13304 (Pubitemid 129518538)
59. Yajima H, Suzuki F. Identification of a Bcl-XL binding region within the ATPase domain of Apaf-1. Biochem Biophys Res Commun 2003;309(3):520-527 (Pubitemid 37083282)
60. Conus S, Rosse T, Borner C. Failure of Bcl-2 family members to interact with Apaf-1 in normal and apoptotic cells. Cell Death Differ 2000;7(10):947-954
61. Finnegan NM, Curtin JF, Prevost G, et al. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 2001;85(1):115-121 (Pubitemid 32695726)
62. Walsh M, Lutz RJ, Cotter TG, et al. Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood 2002;99(9):3439-3448
63. Brewis ND, Phelan A, Normand N, et al. Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis. Mol Ther 2003;7(2):262-270 • This paper describes generation of a vectosome delivery system for a BH3 peptide. (Pubitemid 36395362)
64. Kinoshita M, Hynynen K. Intracellular delivery of Bak BH3 peptide by microbubble-enhanced ultrasound. Pharm Res 2005;22(5):716-720 (Pubitemid 40768582)
65. Dharap SS, Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 2003;20(6):889-896
66. Dharap SS, Qiu B, Williams GC, et al. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 2003;91(1-2):61-73 (Pubitemid 37288877)
67. Dharap SS, Chandna P, Wang Y, et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy. J Pharmacol Exp Ther 2006;316(3):992-998 (Pubitemid 43345270)
68. Li R, Boehm AL, Miranda MB, et al. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia 2007;9(10):801-811 (Pubitemid 47623420)
69. Lama D, Sankararamakrishnan R. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations. Proteins 2008;73(2):492-514
70. Narita M, Shimizu S, Ito T, etal. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 1998;95(25):14681-14686
71. Polster BM, Kinnally KW, Fiskum G. BH3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability. J Biol Chem 2001;276(41):37887-37894 (Pubitemid 37384036)
72. Moreau C, Cartron PF, Hunt A, et al. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem 2003;278(21):19426- 19435 (Pubitemid 36799338)
73. Shangary S, Oliver CL, Tillman TS, et al. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides. Mol Cancer Ther 2004;3(11):1343-1354 (Pubitemid 39567287)
74. Kelekar A, Chang BS, Harlan JE, etal. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol Cell Biol 1997;17(12):7040-7046
75. Ottilie S, Diaz JL, Horne W, et al. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins. J Biol Chem 1997;272(49):30866-30872 (Pubitemid 27527529)
76. Wang JL, Zhang ZJ, Choksi S, etal. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000;60(6):1498-1502
77. Schimmer AD, Hedley DW, Chow S, et al. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ 2001;8(7):725-733 (Pubitemid 32685170)
78. Goldsmith KC, Liu X, Dam V, etal. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene 2006;25(33):4525-4533
79. Kashiwagi H, McDunn JE, Goedegebuure PS, etal. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 2007;14(5):1763-1771
80. Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis invivo by a hydrocarbon-stapled BH3 helix. Science 2004;305(5689):1466-1470 • This paper describes hydrocarbon stapling as a method to stabilize the structure of a BH3 peptide and increase its protease resistance. (Pubitemid 39167667)
81. Oh KJ, Barbuto S, Pitter K, et al. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX invitro. J Biol Chem 2006;281(48):36999-37008 (Pubitemid 46042170)
82. Walensky LD, Pitter K, Morash J, et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 2006;24(2):199-210 (Pubitemid 44557124)
83. Chai J, Du C, Wu JW, etal. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000;406(6798):855-862 •• This work describes the mechanism of apoptosis induction by Smac/DIABLO.
84. Wu G, Chai J, Suber TL, etal. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408(6815):1008-1012
85. Fulda S, Wick W, Weller M, etal. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8(8):808-815
86. Arnt CR, Chiorean MV, Heldebrant MP, et al. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002;277(46):44236-44243
87. Yang L, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 2003;63(4):831-837 (Pubitemid 36231984)
88. Heckl S, Sturzu A, Regenbogen M, et al. A novel polyarginine containing Smac peptide conjugate that mediates cell death in tumor and healthy cells. Med Chem 2008;4(4):348-354
89. Li L, Thomas RM, Suzuki H, etal. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305(5689):1471-1474
90. Mizukawa K, Kawamura A, Sasayama T, et al. Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines. J Neurooncol 2006;77(3):247-255 (Pubitemid 44404390)
91. Sun Y, Ottosson A, Pervaiz S, et al. Smac-mediated sensitization of human B-lymphoma cells to staurosporine- and lactacystin-triggered apoptosis is apoptosome-dependent. Leukemia 2007;21(5):1035-1043 (Pubitemid 46672081)
92. Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008;7:60
93. Fotin-Mleczek M, Welte S, Mader O, et al. Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J Cell Sci 2005;118(Pt 15):3339-3351 (Pubitemid 41246090)
94. Kim D, Jeon C, Kim JH, et al. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm invitro and in vivo. Exp Cell Res 2006;312(8):1277-1288
95. Gao Z, Tian Y, Wang J, etal. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J Biol Chem 2007;282(42):30718-30727 (Pubitemid 350035215)
96. Abhari BA, Davoodi J. A mechanistic insight into SMAC peptide interference with XIAP-Bir2 inhibition of executioner caspases. J Mol Biol 2008;381(3):645-654
97. Nikolovska-Coleska Z, Meagher JL, Jiang S, etal. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal Biochem 2008;374(1):87-98
98. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 2006;58(15):1655-1670 (Pubitemid 44830149)
99. Raucher D, Massodi I, Bidwell GL. Thermally targeted delivery of chemotherapeutics and anti-cancer peptides by elastin-like polypeptide. Expert Opin Drug Deliv 2008;5(3):353-369
100. Lu ZR, Shiah JG, Sakuma S, et al. Design of novel bioconjugates for targeted drug delivery. J Control Release 2002;78(1-3):165-173 (Pubitemid 34081862)
101. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41(2):147-162 (Pubitemid 30122955)
102. Laakkonen P, Zhang L, Ruoslahti E. Peptide targeting of tumor lymph vessels. Ann NY Acad Sci 2008;1131:37-43 (Pubitemid 351758501)
103. Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009;5(1):73-82
104. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786(2):126-138
105. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009;157(2):195-206
106. Schwarze SR, Ho A, Vocero-Akbani A, etal. Invivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285(5433):1569-1572